Suggested remit - To evaluate the benefits and costs of ravulizumab within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria for national commissioning by NHS England
 
Status In progress
Process HST
ID number 1457

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Alexion Pharma UK (ravulizumab)
Others Department of Health and Social Care
  NHS England
  PNH National Services Department of Haematology, Kings College Hospital London
Patient carer groups None
Professional groups Royal College of Physicians

Commentators

Comparator companies None
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
21 April 2020 Topic update: this evaluation has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
07 April 2020 Invitation to participate
26 March 2020 In progress, DHSC referral received.
20 February 2020 - 19 March 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
02 November 2018 (10:00) Scoping workshop (London)
19 September 2018 - 17 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance